Etirinotecan pegol (EP) significantly improves overall survival in patients with advanced breast cancer (aBC) and a history of brain metastases (BM)

O'Shaughnessy, J, Rugo, H, Awada, A et al. (16 more authors) (2016) Etirinotecan pegol (EP) significantly improves overall survival in patients with advanced breast cancer (aBC) and a history of brain metastases (BM). In: European Journal of Cancer. 10th European Breast Cancer Conference (EBCC-10), 09-11 Mar 2016, Amsterdam, Netherlands. Elsevier , S111-S112.

Metadata

Authors/Creators:
  • O'Shaughnessy, J
  • Rugo, H
  • Awada, A
  • Twelves, C
  • Perez, E
  • Im, SA
  • Gomez-Pardo, P
  • Schwartzberg, L
  • Dieras, V
  • Yardley, D
  • Potter, D
  • Mailliez, A
  • Moreno-Aspitia, A
  • Ahn, JS
  • Zhao, C
  • Hoch, U
  • Tagliaferri, M
  • Hannah, A
  • Cortes, J
Dates:
  • Published (online): 10 March 2016
  • Published: April 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 12 Jul 2019 10:11
Last Modified: 12 Jul 2019 10:11
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S0959-8049(16)31962-1
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)